Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RALPH ALHALEL

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1700830353
CMS profile
32241
Location
MCALLEN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$749.94

37 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $749.94 37

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–37 of 37 matching records. This page contains 37 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RALPH ALHALEL

NPI 1700830353 · CMS profile ID 32241

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

MCALLEN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–37 of 37 matching records. This page contains 37 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700830353?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RALPH ALHALEL, NPI 1700830353, CMS profile ID 32241. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–37 of 37 matching records. This page contains 37 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700830353?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). RALPH ALHALEL, NPI 1700830353, CMS profile ID 32241. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–37 of 37 matching records. This page contains 37 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700830353?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
RALPH ALHALEL, NPI 1700830353, CMS profile ID 32241, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–37 of 37 matching records. This page contains 37 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1700830353?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

37 matching records · $749.94 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 37 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–37 of 37.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $5.4412/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684619099 CMS
AbbVie, Inc. $16.4312/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647802113 CMS
AbbVie, Inc. $16.3812/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647802111 CMS
Takeda Pharmaceuticals U.S.A., Inc. $30.3412/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682065073 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.1911/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681981079 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $4.4010/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684619095 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.8010/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682027731 CMS
Takeda Pharmaceuticals U.S.A., Inc. $6.5710/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681681571 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.7409/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681735827 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.7809/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684619091 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.5609/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682088497 CMS
Intercept Pharmaceuticals, Inc. $87.4008/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702060559 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.5408/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681859527 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1.1008/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682089129 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $5.3608/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684619087 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.0208/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681799201 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2.5308/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682036109 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1.4408/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681758167 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.3208/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682103333 CMS
Takeda Pharmaceuticals U.S.A., Inc. $10.4507/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681934659 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.9106/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681890389 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $83.0106/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684619083 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.8405/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682023085 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $1.3804/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684619069 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $0.9604/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684619073 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $7.8804/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684619079 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.0404/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681948355 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1.0604/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682004079 CMS
Gilead Sciences, Inc. $106.5403/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681470485 CMS
Takeda Pharmaceuticals U.S.A., Inc. $7.7903/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681989517 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.3402/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681866017 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1.7602/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682038809 CMS
Allergan Inc. $11.4102/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670017019 CMS
Janssen Biotech, Inc. $17.6602/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658299577 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.0901/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681687647 CMS
Dova Pharmaceuticals $113.6301/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705229719 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.8501/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681685581 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $749.94 37
PY2020 $420.45 27
PY2021 $703.45 46
PY2022 $1,041.54 42
PY2023 $775.96 21
PY2024 $1,310.53 38
PY2025 $447.58 24

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $352,790.88 227
PY2024 Principal investigator $269,533.46 68
PY2023 Principal investigator $335,027.89 61
PY2022 Recipient $1.00 1
PY2022 Principal investigator $35,164.94 37
PY2021 Recipient $938.46 1
PY2021 Principal investigator $34,998.93 15
PY2020 Principal investigator $98,605.96 19
PY2019 Recipient $9,135.15 2
PY2019 Principal investigator $18,309.40 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

227 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $188.50 12/22/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663674
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 12/22/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663676
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 12/22/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663678
Principal investigator 1 Boehringer Ingelheim International GmbH $1,894.10 12/22/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663680
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 12/22/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663682
Principal investigator 1 Boehringer Ingelheim International GmbH $136.50 12/22/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663684
Principal investigator 1 Boehringer Ingelheim International GmbH $93.60 12/22/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663686
Principal investigator 1 Boehringer Ingelheim International GmbH $63.70 12/22/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663688
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 12/17/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663694
Principal investigator 1 Eli Lilly and Company $915.38 12/17/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187875219
Principal investigator 1 Eli Lilly and Company $1,395.66 12/17/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187877063
Principal investigator 1 Genentech, Inc. $3,000.00 12/10/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211580623
Principal investigator 1 Boehringer Ingelheim International GmbH $1,894.10 11/27/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663652
Principal investigator 1 Boehringer Ingelheim International GmbH $750.00 11/26/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663658
Principal investigator 1 Boehringer Ingelheim International GmbH $1,050.00 11/26/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663736
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 11/26/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663738
Principal investigator 1 Boehringer Ingelheim International GmbH $750.00 11/26/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663740
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 11/26/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663742
Principal investigator 1 GlaxoSmithKline, LLC. $650.00 11/20/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192167999
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 11/17/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663646
Principal investigator 1 Boehringer Ingelheim International GmbH $68.90 11/17/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663648
Principal investigator 1 Boehringer Ingelheim International GmbH $67.60 11/17/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663650
Principal investigator 1 Boehringer Ingelheim International GmbH $36.40 11/17/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663654
Principal investigator 1 Boehringer Ingelheim International GmbH $74.10 11/17/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663656
Principal investigator 1 Boehringer Ingelheim International GmbH $45.50 11/17/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663660
Principal investigator 1 Boehringer Ingelheim International GmbH $188.50 11/17/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663662
Principal investigator 1 Boehringer Ingelheim International GmbH $63.70 11/17/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663664
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 11/17/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663666
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 11/17/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663668
Principal investigator 1 Boehringer Ingelheim International GmbH $41.60 11/17/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663670
Principal investigator 1 Boehringer Ingelheim International GmbH $93.60 11/17/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663672
Principal investigator 1 Phathom Pharmaceuticals, Inc. $600.00 11/14/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
EoE-201 No dispute reported 06/30/2026 1224869015
Principal investigator 1 Phathom Pharmaceuticals, Inc. $1,250.00 11/14/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
EoE-201 No dispute reported 06/30/2026 1224869019
Principal investigator 1 Phathom Pharmaceuticals, Inc. $2,000.00 11/03/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
EoE-201 No dispute reported 06/30/2026 1224869060
Principal investigator 1 Boehringer Ingelheim International GmbH $1,200.00 10/30/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663734
Principal investigator 1 Boehringer Ingelheim International GmbH $36.40 10/27/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663540
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 10/27/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663544
Principal investigator 1 Boehringer Ingelheim International GmbH $2,678.00 10/27/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663576
Principal investigator 1 Boehringer Ingelheim International GmbH $596.05 10/27/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663582
Principal investigator 1 Boehringer Ingelheim International GmbH $1,894.10 10/27/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663584
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 10/27/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663588
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 10/27/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663594
Principal investigator 1 Boehringer Ingelheim International GmbH $41.60 10/27/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663596
Principal investigator 1 Boehringer Ingelheim International GmbH $36.40 10/27/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663634
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 10/27/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663690
Principal investigator 1 Boehringer Ingelheim International GmbH $2.00 10/27/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663692
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 10/27/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663744
Principal investigator 1 Boehringer Ingelheim International GmbH $279.72 10/27/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663746
Principal investigator 1 Boehringer Ingelheim International GmbH $839.50 10/27/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663748
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 10/27/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663750
Principal investigator 1 Boehringer Ingelheim International GmbH $15,715.70 10/16/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663624
Principal investigator 1 Boehringer Ingelheim International GmbH $815.10 10/16/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663630
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663538
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663542
Principal investigator 1 Boehringer Ingelheim International GmbH $89.70 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663546
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663548
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663550
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663552
Principal investigator 1 Boehringer Ingelheim International GmbH $63.70 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663554
Principal investigator 1 Boehringer Ingelheim International GmbH $63.70 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663556
Principal investigator 1 Boehringer Ingelheim International GmbH $36.40 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663558
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663560
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663562
Principal investigator 1 Boehringer Ingelheim International GmbH $63.70 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663564
Principal investigator 1 Boehringer Ingelheim International GmbH $41.60 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663566
Principal investigator 1 Boehringer Ingelheim International GmbH $93.60 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663568
Principal investigator 1 Boehringer Ingelheim International GmbH $68.90 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663570
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663572
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663574
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663578
Principal investigator 1 Boehringer Ingelheim International GmbH $36.40 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663580
Principal investigator 1 Boehringer Ingelheim International GmbH $36.40 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663586
Principal investigator 1 Boehringer Ingelheim International GmbH $89.70 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663590
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663592
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663598
Principal investigator 1 Boehringer Ingelheim International GmbH $68.90 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663600
Principal investigator 1 Boehringer Ingelheim International GmbH $188.50 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663602
Principal investigator 1 Boehringer Ingelheim International GmbH $93.60 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663604
Principal investigator 1 Boehringer Ingelheim International GmbH $104.00 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663606
Principal investigator 1 Boehringer Ingelheim International GmbH $188.50 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663608
Principal investigator 1 Boehringer Ingelheim International GmbH $104.00 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663610
Principal investigator 1 Boehringer Ingelheim International GmbH $93.60 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663612
Principal investigator 1 Boehringer Ingelheim International GmbH $188.50 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663614
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663616
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663618
Principal investigator 1 Boehringer Ingelheim International GmbH $104.00 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663620
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663622
Principal investigator 1 Boehringer Ingelheim International GmbH $93.60 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663626
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663628
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663632
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663636
Principal investigator 1 Boehringer Ingelheim International GmbH $89.70 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663638
Principal investigator 1 Boehringer Ingelheim International GmbH $63.70 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663640
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663642
Principal investigator 1 Boehringer Ingelheim International GmbH $188.50 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663644
Principal investigator 1 Boehringer Ingelheim International GmbH $850.00 10/03/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663732
Principal investigator 1 Boehringer Ingelheim International GmbH $596.05 09/29/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663504
Principal investigator 1 Boehringer Ingelheim International GmbH $2,256.80 09/29/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663516
Principal investigator 1 Boehringer Ingelheim International GmbH $3,247.40 09/29/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663518
Principal investigator 1 Boehringer Ingelheim International GmbH $15,715.70 09/29/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663530
Principal investigator 1 Boehringer Ingelheim International GmbH $1,200.00 09/26/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663508
Principal investigator 1 Genentech, Inc. $3,100.00 09/26/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211580594
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 09/24/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663494
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 09/24/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663496
Principal investigator 1 Boehringer Ingelheim International GmbH $657.00 09/24/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663498
Principal investigator 1 Genentech, Inc. $34,776.00 09/24/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211580532
Principal investigator 1 Genentech, Inc. $200.00 09/24/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211580578
Principal investigator 1 Genentech, Inc. $400.00 09/24/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211580582
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 09/15/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663500
Principal investigator 1 Boehringer Ingelheim International GmbH $8,050.00 09/15/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663730
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/11/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663502
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 09/11/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663506
Principal investigator 1 Boehringer Ingelheim International GmbH $260.00 09/11/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663510
Principal investigator 1 Boehringer Ingelheim International GmbH $74.10 09/11/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663512
Principal investigator 1 Boehringer Ingelheim International GmbH $93.60 09/11/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663514
Principal investigator 1 Boehringer Ingelheim International GmbH $45.50 09/11/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663520
Principal investigator 1 Boehringer Ingelheim International GmbH $63.70 09/11/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663522
Principal investigator 1 Boehringer Ingelheim International GmbH $188.50 09/11/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663524
Principal investigator 1 Boehringer Ingelheim International GmbH $41.60 09/11/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663526
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 09/11/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663528
Principal investigator 1 Boehringer Ingelheim International GmbH $104.00 09/11/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663532
Principal investigator 1 Boehringer Ingelheim International GmbH $89.70 09/11/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663534
Principal investigator 1 Boehringer Ingelheim International GmbH $91.00 09/11/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663536
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 08/26/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663492
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 08/22/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192167985
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 08/22/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192168003
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 08/15/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192167982
Principal investigator 1 GlaxoSmithKline, LLC. $1,800.00 08/15/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192167990
Principal investigator 1 Boehringer Ingelheim International GmbH $15,715.70 07/30/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663452
Principal investigator 1 Boehringer Ingelheim International GmbH $15,715.70 07/30/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663454
Principal investigator 1 Boehringer Ingelheim International GmbH $15,715.70 07/30/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663456
Principal investigator 1 Boehringer Ingelheim International GmbH $15,715.70 07/30/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663458
Principal investigator 1 Boehringer Ingelheim International GmbH $15,715.70 07/30/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663460
Principal investigator 1 Boehringer Ingelheim International GmbH $15,715.70 07/30/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663462
Principal investigator 1 Boehringer Ingelheim International GmbH $16,560.70 07/30/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663728
Principal investigator 1 Genentech, Inc. $1,107.00 07/30/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211580574
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 07/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663486
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 07/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663488
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 07/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663490
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 07/25/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663466
Principal investigator 1 Boehringer Ingelheim International GmbH $4.47 07/25/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663468
Principal investigator 1 Boehringer Ingelheim International GmbH $207.38 07/25/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663470
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 07/25/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663472
Principal investigator 1 Boehringer Ingelheim International GmbH $124.00 07/25/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663474
Principal investigator 1 Boehringer Ingelheim International GmbH $72.00 07/25/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663476
Principal investigator 1 Boehringer Ingelheim International GmbH $2.92 07/25/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663478
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 07/25/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663480
Principal investigator 1 Boehringer Ingelheim International GmbH $11.32 07/25/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663482
Principal investigator 1 Boehringer Ingelheim International GmbH $190.50 07/25/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663484
Principal investigator 1 Boehringer Ingelheim International GmbH $104.00 07/23/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663436
Principal investigator 1 Boehringer Ingelheim International GmbH $188.50 07/23/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663438
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 07/23/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663440
Principal investigator 1 Boehringer Ingelheim International GmbH $93.60 07/23/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663442
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 07/23/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663444
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 07/23/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663446
Principal investigator 1 Boehringer Ingelheim International GmbH $36.40 07/23/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663448
Principal investigator 1 Boehringer Ingelheim International GmbH $89.70 07/23/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663450
Principal investigator 1 Boehringer Ingelheim International GmbH $63.70 07/23/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663464
Principal investigator 1 Genentech, Inc. $837.00 07/04/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211580556
Principal investigator 1 Genentech, Inc. $2,736.00 07/02/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211580547
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,076.80 07/02/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282080
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 06/24/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663724
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 06/24/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663726
Principal investigator 1 Genentech, Inc. $5,535.00 06/23/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211580516
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 06/11/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192167995
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 05/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663402
Principal investigator 1 Boehringer Ingelheim International GmbH $93.60 05/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663404
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 05/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663406
Principal investigator 1 Boehringer Ingelheim International GmbH $1,072.50 05/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663408
Principal investigator 1 Boehringer Ingelheim International GmbH $1,114.10 05/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663410
Principal investigator 1 Boehringer Ingelheim International GmbH $63.70 05/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663412
Principal investigator 1 Boehringer Ingelheim International GmbH $104.00 05/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663414
Principal investigator 1 Boehringer Ingelheim International GmbH $36.40 05/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663416
Principal investigator 1 Boehringer Ingelheim International GmbH $908.70 05/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663418
Principal investigator 1 Boehringer Ingelheim International GmbH $89.70 05/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663420
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 05/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663422
Principal investigator 1 Boehringer Ingelheim International GmbH $296.40 05/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663426
Principal investigator 1 Boehringer Ingelheim International GmbH $188.50 05/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663428
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 05/27/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663432
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 05/27/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663434
Principal investigator 1 Boehringer Ingelheim International GmbH $490.10 05/22/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663716
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 05/15/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663712
Principal investigator 1 Boehringer Ingelheim International GmbH $36.40 05/15/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663714
Principal investigator 1 Boehringer Ingelheim International GmbH $89.70 05/15/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663718
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 05/15/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663720
Principal investigator 1 Boehringer Ingelheim International GmbH $104.00 05/15/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663722
Principal investigator 1 Boehringer Ingelheim International GmbH $63.70 05/07/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663384
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 05/07/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663386
Principal investigator 1 Boehringer Ingelheim International GmbH $93.60 05/07/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663388
Principal investigator 1 Boehringer Ingelheim International GmbH $104.00 05/07/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663390
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 05/07/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663392
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 05/07/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663394
Principal investigator 1 Boehringer Ingelheim International GmbH $36.40 05/07/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663398
Principal investigator 1 Boehringer Ingelheim International GmbH $89.70 05/07/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663400
Principal investigator 1 Boehringer Ingelheim International GmbH $188.50 05/07/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663424
Principal investigator 1 Boehringer Ingelheim International GmbH $3,250.00 05/05/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663396
Principal investigator 1 Boehringer Ingelheim International GmbH $3,250.00 05/05/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663710
Principal investigator 1 Boehringer Ingelheim International GmbH $1,050.00 05/01/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663382
Principal investigator 1 Phathom Pharmaceuticals, Inc. $14,500.00 05/01/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
EoE-201 No dispute reported 06/30/2026 1224868927
Principal investigator 1 Phathom Pharmaceuticals, Inc. $14,500.00 05/01/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
EoE-201 No dispute reported 06/30/2026 1224868930
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 04/23/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663430
Principal investigator 1 Genentech, Inc. $1,107.00 04/04/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211580512
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 03/25/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663372
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 03/25/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663374
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 03/25/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663376
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 03/25/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663378
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 03/25/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663380
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 03/25/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663700
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 03/25/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663702
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 03/25/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663704
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 03/25/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663706
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 03/25/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663708
Principal investigator 1 Genentech, Inc. $18,414.00 03/05/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211580445
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 02/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663352
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 02/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663354
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 02/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663360
Principal investigator 1 Boehringer Ingelheim International GmbH $12.86 02/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663362
Principal investigator 1 Boehringer Ingelheim International GmbH $239.89 02/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663364
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 02/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663366
Principal investigator 1 Boehringer Ingelheim International GmbH $21.43 02/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663368
Principal investigator 1 Boehringer Ingelheim International GmbH $33.71 02/28/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663370
Principal investigator 1 Boehringer Ingelheim International GmbH $6,000.00 02/13/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663356
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 02/13/2025 Non-covered Recipient Entity
Brcr Global Texas
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220663358
Principal investigator 1 Boehringer Ingelheim International GmbH $6,000.00 02/13/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663696
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 02/13/2025 Non-covered Recipient Entity
Brcr Global Texas
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220663698
Principal investigator 1 Genentech, Inc. $2,270.00 01/29/2025 Non-covered Recipient Entity
DIGESTIVE HEALTH PARTNERS PA
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211596852
Principal investigator 1 GlaxoSmithKline, LLC. $2,963.00 01/28/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192167977